GlassScriptPhysician profile
Martin K Erickson
NPI 1326028523
$11,786.06
in general payments reported to CMS, 2019-2025
56 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $1,171 · 2021: $1,997 · 2022: $1,930 · 2023: $1,540 · 2024: $1,649 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,979.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,938.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,257.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $996.25 | 2019-2025 | Jardiance, Glyxambi, Tradjenta |
| Abbvie INC. | $730.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $650.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $586.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $501.72 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $500.32 | 2019-2023 | Xarelto |
| Pfizer INC. | $472.72 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $422.15 | 2019-2024 | Austedo Xr, Ajovy |
| Amgen INC. | $355.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $333.92 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.58 | 2021-2024 | |
| Nestle Healthcare Nutrition INC. | $314.42 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $215.46 | 2023-2025 | Rexulti |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.